124 results on '"Imbert S"'
Search Results
2. Severe kerion Celsi caused by Trichophyton quinckeanum
- Author
-
Lefranc, M., primary, Fourmond, S., additional, Jabet, A., additional, Normand, A-C, additional, Girard, D., additional, Accoceberry, I., additional, Gabriel, F., additional, Delhaes, L., additional, and Imbert, S., additional
- Published
- 2024
- Full Text
- View/download PDF
3. Features of cryptococcosis among 652 HIV-seronegative individuals in France: a cross-sectional observational study (2005-2020)
- Author
-
Paccoud, Olivier, primary, Desnos-Ollivier, Marie, additional, Persat, Florence, additional, Demar, Magalie, additional, Boukris-Sitbon, Karine, additional, Bellanger, Anne-Pauline, additional, Bonhomme, Julie, additional, Bonnal, Christine, additional, Botterel, Françoise, additional, Bougnoux, Marie-Elisabeth, additional, Brun, Sophie, additional, Cassaing, Sophie, additional, Cateau, Estelle, additional, Chouaki, Taieb, additional, Cornet, Muriel, additional, Dannaoui, Eric, additional, Desbois-Nogard, Nicole, additional, Durieux, Marie-Fleur, additional, Favennec, Loïc, additional, Fekkar, Arnaud, additional, Gabriel, Frederic, additional, Gangneux, Jean-Pierre, additional, Guitard, Juliette, additional, Hasseine, Lilia, additional, Huguenin, Antoine, additional, Le Gal, Solène, additional, Letscher-Bru, Valérie, additional, Mahinc, Caroline, additional, Morio, Florent, additional, Nicolas, Muriel, additional, Poirier, Philippe, additional, Ranque, Stéphane, additional, Roosen, Gabrielle, additional, Rouges, Célia, additional, Roux, Anne-Laure, additional, Sasso, Milène, additional, Alanio, Alexandre, additional, Lortholary, Olivier, additional, Lanternier, Fanny, additional, Brieu, N., additional, Durand, C., additional, Bertei, D., additional, Bouchara, J.P., additional, Pihet, M., additional, Bland, S., additional, Bru (Annecy), J.P., additional, Pulik, M., additional, Le Turdu, F., additional, Lefrand, C, H., additional, Ferrand, M., additional, Larrouy, M., additional, Millon, L., additional, Delhaes, L., additional, Imbert, S., additional, Accoceberry, I., additional, Bachelier, M.N., additional, Nevez, G., additional, Quinio, D., additional, Le Coustumier, A., additional, Carmagnol, F., additional, Rivière, B., additional, Boex, P., additional, Podac, B., additional, Moniot, M., additional, Nourrisson, C., additional, Augereau, O., additional, Emond, J.P., additional, Belkacem-Belkaki, G., additional, Bacri, J.L., additional, Berthelot, G., additional, Dalle, F., additional, Vallee, E., additional, Bizet, J., additional, Noussair, L., additional, Herrmann, J.L., additional, Maubon, D., additional, Brocard, C., additional, Guiffault, P., additional, Layet, A., additional, Morel, A., additional, Angoulvant, A., additional, Penn, P., additional, Gigandon, A., additional, Sendid, B., additional, Cornu, M., additional, Darde, M.L., additional, Jaccard, A., additional, Bouteille, B., additional, Azjenberg, D., additional, Prades, N., additional, Bienvenu, A.L., additional, Benoit-Cattin, T., additional, Fiacre, A., additional, Levy, S., additional, Pitsch, A., additional, Kiefer, M.H., additional, Debourgogne, A., additional, Moquet, O., additional, Colot, J., additional, Courtellemont, L., additional, Poisson, D., additional, Laurens, V., additional, Kauffmann-Lacroix, C., additional, Martres, P., additional, Gargala, G., additional, Godineau, N., additional, Picot, S., additional, Chassagne, C., additional, Djibo, N., additional, Devallière, R., additional, Sabou, M., additional, Camin-Ravenne, A.M., additional, Bissuel, F., additional, Janvier, F., additional, Aubert, X., additional, Chadapaud, S., additional, Delbeck, X., additional, Lafeuillade, A., additional, Raoult, X., additional, Baclet, V., additional, Coignard, C., additional, Mouton, Y., additional, Ravaux, I., additional, Eloy, C., additional, Fur, A., additional, Rezzouk, L., additional, Mazards, E., additional, Eloy, O., additional, Chachaty, E., additional, Mihaila, L., additional, Dellion, S., additional, Patey, O., additional, Thouvenot, A., additional, Limousin, L., additional, Paugam, A., additional, Desplaces, N., additional, Raguin, G., additional, Sitterlé, E., additional, Blaize, M., additional, Gits-Muselli, M., additional, Hennequin, C., additional, Poirot, J.L., additional, Bretagne, S., additional, Lacroix, Claire, additional, and Hamane, Samia, additional
- Published
- 2024
- Full Text
- View/download PDF
4. Performances diagnostiques de la PCR Mucorales sur prélèvements respiratoires profonds
- Author
-
Brousse, X., primary, Imbert, S., additional, Issa, N., additional, Forcade, E., additional, Faure, M., additional, Chambord, J., additional, Ramaroson, H., additional, Kaminski, H., additional, Dumas, P., additional, and Blanchard, E., additional
- Published
- 2023
- Full Text
- View/download PDF
5. Interpretation of the Elecsys Toxo IgG avidity results for very low and very high index: study on 741 sera with a determined date of toxoplasmosis
- Author
-
Fricker-Hidalgo, H., L’Ollivier, C., Bosson, C., Imbert, S., Bailly, S., Dard, C., Piarroux, R., Paris, L., and Pelloux, H.
- Published
- 2017
- Full Text
- View/download PDF
6. Multicentric Analysis of the Species Distribution and Antifungal Susceptibility of Clinical Isolates from Aspergillus Section Circumdati
- Author
-
Imbert, S., primary, Normand, A. C., additional, Costa, D., additional, Gabriel, F., additional, Lachaud, L., additional, Schuttler, C., additional, Cassaing, S., additional, Mahinc, C., additional, Hasseine, L., additional, Demar, M., additional, Brun, S., additional, Bonnal, C., additional, Moreno-Sabater, A., additional, Becker, P., additional, Piarroux, R., additional, and Fekkar, A., additional
- Published
- 2023
- Full Text
- View/download PDF
7. A Multiplex PCR and DNA-Sequencing Workflow on Serum for the Diagnosis and Species Identification for Invasive Aspergillosis and Mucormycosis
- Author
-
Imbert, S., primary, Portejoie, L., additional, Pfister, E., additional, Tauzin, B., additional, Revers, M., additional, Uthurriague, J., additional, Hernandez-Grande, M., additional, Lafon, M.-E, additional, Jubert, C., additional, Issa, N., additional, Dumas, P.-Y, additional, and Delhaes, L., additional
- Published
- 2023
- Full Text
- View/download PDF
8. Combined Bacterial Meningitis and Infective Endocarditis: When Should We Search for the Other When Either One is Diagnosed?
- Author
-
Béraud, Guillaume, Tubiana, Sarah, Erpelding, Marie-Line, Le Moing, Vincent, Chirouze, Catherine, Gorenne, Isabelle, Manchon, Pauline, Tattevin, Pierre, Vernet, Veronique, Varon, Emmanuelle, Hoen, Bruno, Duval, Xavier, Obadia, J., Leport, C., Poyart, C., Revest, M., Selton-Suty, C., Strady, C., Vandenesch, F., Bernard, Y., Chocron, S., Plesiat, P., Abouliatim, I., de Place, C., Donnio, P., Alla, F., Carteaux, J., Doco-Lecompte, T., Lion, C., Aissa, N., Baehrel, B., Jaussaud, R., Nazeyrollas, P., Cambau, E., Iung, B., Nataf, P., Chidiac, C., Celard, M., Delahaye, F., Aumaître, H., Frappier, J., Oziol, E., Sotto, A., Sportouch, C., Bouvet, A., Bes, M., Abassade, P., Abrial, E., Acar, C., Alexandra, J., Amireche, N., Amrein, D., Andre, P., Appriou, M., Arnould, M., Atoui, A., Aziza, F., Baille, N., Bajolle, N., Battistella, P., Baumard, S., Ben Ali, A., Bertrand, J., Bialek, S., Bois Grosse, M., Boixados, M., Borlot, F., Bouchachi, A., Bouche, O., Bouchemal, S., Bourdon, J., Brasme, L., Bruntz, J., Cailhol, J., Caplan, M.P., Carette, B., Cartry, O., Cazorla, C., Chamagne, H., Champagne, H., Chanques, G., Chevalier, B., Chometon, F., Christophe, C., Colin de Verdiere, N., Daneluzzi, V., David, L., Danchin, N., de Lentdecker, P., Delcey, V., Deleuze, P., Deroure, B., Descotes-Genon, V., Didier Petit, K., Dinh, A., Doat, V., Duchene, F., Duhoux, F., Dupont, M., Ederhy, S., Epaulard, O., Evest, M., Faucher, J., Fauveau, E., Ferry, T., Fillod, M., Floch, T., Fraisse, T., Frapier, J., Freysz, L., Fumery, B., Gachot, B., Gallien, S., Garcon, P., Gaubert, A., Genoud, J., Ghiglione, S., Godreuil, C., Gandjbakhch, I., Grentzinger, A., Groben, L., Gherissi, D., Hagege, A., Hammoudi, N., Heliot, F., Henry, P., Houriez, P., Hustache-Mathieu, L., Huttin, O., Imbert, S., Jaureguiberry, S., Kaaki, M., Konate, A., Kuhn, J., Kural Menasche, S., Lafitte, A., Lafon, B., Lanternier, F., Le Chenault, V., Lechiche, C., Lefevre Thibaut, S., Lefort, A., Lemoine, J., Lepage, L., Lepousé, C., Leroy, J., Lesprit, P., Letranchant, L., Loncar, G., Lorentz, C., Magnin-Poull, I., Makinson, A., Man, H., Mansouri, M., Marçon, O., Maroni, J., Masse, V., Maurier, F., Mechaï, F., Merceron, O., Messika-Zeitoun, D., Metref, Z., Meyssonnier, V., Mezher, C., Micheli, S., Monsigny, M., Mouly, S., Mourvillier, B., Nallet, O., Nazerollas, P., Noel, V., Payet, B., Pelletier, A., Perez, P., Petit, J., Philippart, F., Piet, E., Plainvert, C., Popovic, B., Porte, J., Pradier, P., Ramadan, R., Richemond, J., Rodermann, M., Roncato, M., Roigt, I., Ruyer, O., Saada, M., Schwartz, J., Simon, M., Simorre, B., Skalli, S., Spatz, F., Sudrial, J., Tartiere, L., Terrier de La Chaize, A., Thiercelin, M., Thomas, D., Thomas, M., Toko, L., Tournoux, F., Tristan, A., Trouillet, J., Tual, L., Verdier, F., Vernet Garnier, V., Vidal, V., Weyne, P., Wolff, M., Wynckel, A., Zannad, N., Zinzius, P., Ploy, M.-C., Caron, F., Bollaert, P.-E., Gaillot, O., Taha, M.-K., Bonacorsi, S., Lecuit, M., Gravet, A., Frachet, B., Debroucker, T., Levy-Bruhl, D., Raffi, F., Preau, M., Anguel, N., Argaud, L., Arista, S., Armand-Lefevre, L., Balavoine, S., Baraduc, R., Barnaud, G., Bernard, L., Bernars, G., Bertei, D., Bessede, E., Billard Pomares, T., Biron, C., Bland, S., Boileau, J., Boubeau, P., Bourdon, S., Bousquet, A., Boyer, S., Bozorg-Grayeli, A., Bret, L., Bretonniere, C., Bricaire, F., Brocas, E., Brun, M., Buret, J., Burucoa, C., Cabalion, J., Cabon, M., Camuset, G., Canevet, C., Carricajo, A., Castan, B., Caumes, E., Cazanave, C., Chabrol, A., Challan-Belval, T., Chanteperdrix-Marillier, V., Chaplain, C., Charlier-Woerther, C., Chaussade, H., Clair, B., Colot, J., Conil, J.-M., Cordel, H., Cormier, P., Cousson, J., Cronier, P., Cua, E., Dao-Dubremetz, A., Dargere, S., Degand, N., Dekeyser, S., Delaune, D., Denes, E., Dequin, P.-F., Descamps, D., Descloux, E., Desmaretz, J.-L., Diehl, J.-L., Dimet, J., Escaut, L., Fabe, C., Faibis, F., Flateau, C., Fonsale, N., Forestier, E., Fortineau, N., Gagneux-Brunon, A., Garandeau, C., Garcia, M., Garot, D., Gaudry, S., Goehringer, F., Gregoire-Faucher, V., Grosset, M., Gubavu, C., Gueit, I., Guelon, D., Guimard, T., Guinard, J., Hadou, T., Helene, J.-P., Henard, S., Henry, B., Hochart, A.-C., Illes, G., Jaffuel, S., Jarrin, I., Jaureguy, F., Joseph, C., Juvin, M.-E., Kayal, S., Kerneis, S., Lacassin, F., Lamaury, I., Lanotte, P., Laurens, E., Laurichesse, H., Le Brun, C., Le Turnier, P., Lecuyer, H., Ledru, S., Legrix, C., Lemaignen, A., Lemble, C., Lemee, L., Lesens, O., Levast, M., Lhommet, C., Males, S., Malpote, E., Martin-Blondel, G., Marx, M., Masson, R., Matray, O., Mbadi, A., Mellon, G., Merens, A., Meyohas, M.-C., Michon, A., Mootien Yoganaden, J., Morquin, D., Mrozek, N., Nguyen, S., Nguyen, Y., Ogielska, M., Page, B., Patrat-Delon, S., Patry, I., Pechinot, A., Picot, S., Pierrejean, D., Piroth, L., Plassart, C., Plessis, P., Portel, L., Poubeau, P., Poupard, M., Prazuck, T., Quaesaet, L., Ramanantsoa, A., Rapp, C., Raskine, L., Raymond, J., Riche, A., Robaday-Voisin, S., Robin, F., Romaszko, J.-P., Rousseau, F., Roux, A.-L., Royer, C., Salmon, D., Saroufim, C., Schmit, J.-L., Sebire, M., Segonds, C., Sivadon-Tardy, V., Soismier, N., Son, O., Sunder, S., Suy, F., Tande, D., Tankovic, J., Valin, N., van Grunderbeeck, N., Verdon, R., Vergnaud, M., Vernet-Garnier, V., Vidal, M., Vitrat, V., Vittecoq, D., Vuotto, F., Laouenan, C., Marcault, E., Mentre, F., Pasquet, B., Roy, C., Centre hospitalier universitaire de Poitiers (CHU Poitiers), Centre d'investigation Clinique [CHU Bichat] - Épidémiologie clinique (CIC 1425), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, Centre d'investigation clinique [Nancy] (CIC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Laboratoire Chrono-environnement (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), CHU Pontchaillou [Rennes], ARN régulateurs bactériens et médecine (BRM), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPC)-Université Sorbonne Paris Nord, Centre d'investigation clinique - Epidémiologie clinique [Nancy] (CIC-EC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Centre Hospitalier Universitaire de Reims (CHU Reims), Centre Hospitalier Intercommunal de Créteil (CHIC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), and The AEPEI IE cohort was funded by a research grant from the French Ministry of Health (PHRC 2007), grants from the Société Française de Cardiologie, the European Society of Clinical Microbiology and Infectious Diseases, and Novartis France. The sponsor was Délégation à la Recherche Clinique et au Développement, Centre Hospitalier Universitaire de Besançon. The COMBAT cohort was funded by Assistance Publique—Hôpitaux de Paris, Inserm, The French Society of Infectious Diseases (SPILF), and Pfizer Laboratory. It was also supported by the Observatoire de la Resistance du Pneumocoque (ORP) and Santé Publique France. The sponsor of the study and the funding sources had no role in study design, data collection, data analysis, data interpretation or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit it for publication. The Rapid Service Fee was funded by the University Hospital of Poitiers, to which the corresponding author is affiliated.
- Subjects
Microbiology (medical) ,Infectious Diseases ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Echocardiography ,Austrian syndrome ,Staphylococcus ,[SDV]Life Sciences [q-bio] ,Bacterial meningitis ,Streptococcus ,Infective endocarditis - Abstract
International audience; Introduction: We aimed to describe patients with coexisting infective endocarditis (IE) and bacterial meningitis (BM).Methods: We merged two large prospective cohorts, an IE cohort and a BM cohort, with only cases of definite IE and community-acquired meningitis. We compared patients who had IE and BM concurrently to patients with IE only and BM only.Results: Among the 1030 included patients, we identified 42 patients with IE-BM (4.1%). Baseline characteristics of patients with IE-BM were mostly similar to those of patients with IE, but meningitis was the predominant presentation at admission (39/42, 92.3%). Causative pathogens were predominantly Streptococcus pneumoniae (18/42, 42.9%) and Staphylococcus aureus (14/42, 33.3%). All pneumococcal IE were associated with BM (18/18). BM due to oral and group D streptococci, Streptococcus agalactiae, and S. aureus were frequently associated with IE (14/30, 46.7%). Three-month mortality was 28.6% in patients with IE-BM, 20.5% in patients with IE, and 16.6% in patients with BM.Conclusions: Patients with pneumococcal IE or altered mental status during IE must be investigated for BM. Patients with S. aureus, oral and group D streptococcal or enterococcal BM, or unfavorable outcome in pneumococcal meningitis would benefit from an echocardiography. Patients with the dual infection have the worst prognosis. Their identification is mandatory to initiate appropriate treatment.
- Published
- 2022
- Full Text
- View/download PDF
9. Mise au point d'une stratégie de diagnostic étiologique des mucormycoses par séquençage.
- Author
-
Pfister, E., primary, Tauzin, B., additional, Lafon, M., additional, Imbert, S., additional, and Delhaes, L., additional
- Published
- 2022
- Full Text
- View/download PDF
10. Emergence of echinocandin-resistant Candida spp. in a hospital setting: a consequence of 10 years of increasing use of antifungal therapy?
- Author
-
Fekkar, A., Dannaoui, E., Meyer, I., Imbert, S., Brossas, J. Y., Uzunov, M., Mellon, G., Nguyen, S., Guiller, E., Caumes, E., Leblond, V., Mazier, D., Fievet, M. H., and Datry, A.
- Published
- 2014
- Full Text
- View/download PDF
11. Use of Total Error concept in the validation of viral activity in cell cultures
- Author
-
Gibelin, N., Dupont, D., Imbert, S., and Rozet, E.
- Published
- 2009
- Full Text
- View/download PDF
12. Aspergillus PCR in serum for the diagnosis, follow-up and prognosis of invasive aspergillosis in neutropenic and nonneutropenic patients
- Author
-
Imbert, S., Gauthier, L., Joly, I., Brossas, J.-Y., Uzunov, M., Touafek, F., Brun, S., Mazier, D., Datry, A., Gay, F., and Fekkar, A.
- Published
- 2016
- Full Text
- View/download PDF
13. Utilisation du mélange équimolaire de protoxyde d’azote/oxygène et du bloc fémoral pour la prise en charge antalgique des fractures du col du fémur dans un service d’urgences
- Author
-
Murgue, D., Ehret, B., Massacrier-Imbert, S., Durand, O., Gibaud, F., Maakel, A., and Castelain, S.
- Published
- 2006
- Full Text
- View/download PDF
14. Multicentric Analysis of the Species Distribution and Antifungal Susceptibility of Cryptic Isolates from Aspergillus Section Fumigati
- Author
-
Imbert, S., primary, Normand, A. C., additional, Cassaing, S., additional, Gabriel, F., additional, Kristensen, L., additional, Bonnal, C., additional, Lachaud, L., additional, Costa, D., additional, Guitard, J., additional, Hasseine, L., additional, Palous, M., additional, Piarroux, M., additional, Hendrickx, M., additional, Piarroux, R., additional, and Fekkar, A., additional
- Published
- 2020
- Full Text
- View/download PDF
15. Unexpected mould diversity in clinical isolates from French Guiana and associated identification difficulties
- Author
-
Nabet, C, primary, Imbert, S, additional, Normand, A C, additional, Blanchet, D, additional, Chanlin, R, additional, Becker, P, additional, Demar, M, additional, and Piarroux, R, additional
- Published
- 2020
- Full Text
- View/download PDF
16. Species Distribution and Comparison between EUCAST and Gradient Concentration Strips Methods for Antifungal Susceptibility Testing of 112 Aspergillus Section Nigri Isolates
- Author
-
Carrara, B., primary, Richards, R., additional, Imbert, S., additional, Morio, F., additional, Sasso, M., additional, Zahr, N., additional, Normand, A. C., additional, Le Pape, P., additional, Lachaud, L., additional, Ranque, S., additional, Maubon, D., additional, Piarroux, R., additional, and Fekkar, A., additional
- Published
- 2020
- Full Text
- View/download PDF
17. Simple Scoring System to Predict In‐Hospital Mortality After Surgery for Infective Endocarditis
- Author
-
Gatti, Giuseppe, Perrotti, Andrea, Obadia, Jean-François, Duval, Xavier, Iung, Bernard, Alla, François, Chirouze, Catherine, Selton-Suty, Christine, Hoen, Bruno, Sinagra, Gianfranco, Delahaye, François, Tattevin, Pierre, Le Moing, Vincent, Pappalardo, Aniello, Chocron, Sidney, Hoen, B., Duval, X., Alla, F., Bouvet, A., Briancon, S., Cambau, E., Celard, M., Chirouze, C., Danchin, N., Doco-Lecompte, T., Delahaye, F., Etienne, J., Iung, B., Le Moing, V., Obadia, J. F., Leport, C., Poyart, C., Revest, M., Selton-Suty, C., Strady, C., Tattevin, P., Vandenesch, F., Bernard, Y., Chocron, S., Plesiat, P., Abouliatim, I., De Place, C., Donnio, P. Y., Carteaux, J. P., Lion, C., Aissa, N., Baehrel, B., Jaussaud, R., Nazeyrollas, P., Vernet, V., Nataf, P., Chidiac, C., Aumaître, H., Frappier, J. M., Oziol, E., Sotto, A., Sportouch, C., Bes, M., Abassade, P., Abrial, E., Acar, C., Alexandra, J. F., Amireche, N., Amrein, D., Andre, P., Appriou, M., Arnould, M. A., Assayag, P., Atoui, A., Aziza, F., Baille, N., Bajolle, N., Battistella, P., Baumard, S., Ben Ali, A., Bertrand, J., Bialek, S., Bois Grosse, M., Boixados, M., Borlot, F., Bouchachi, A., Bouche, O., Bouchemal, S., Bourdon, J. L., Brasme, L., Bricaire, F., Brochet, E., Bruntz, J. F., Cady, A., Cailhol, J., Caplan, M. P., Carette, B., Cartry, O., Cazorla, C., Chamagne, H., Champagne, H., Chanques, G., Chastre, J., Chevalier, B., Chometon, F., Christophe, C., Cohen, A., Colin de Verdiere, N., DANELUZZI, VALERIA, David, L., De Lentdecker, P., Delcey, V., Deleuze, P., Donal, E., Deroure, B., Descotes-Genon, V., Didier Petit, K., Dinh, A., Doat, V., Duchene, F., Duhoux, F., Dupont, M., Ederhy, S., Epaulard, O., Evest, M., Faucher, J. F., FANTIN, BARBARA, Fauveau, E., Ferry, T., Fillod, M., Floch, T., Fraisse, T., Frapier, J. M., Freysz, L., Fumery, B., Gachot, B., Gallien, S., Gandjbach, I., Garcon, P., Gaubert, A., Genoud, J. L., Ghiglione, S., Godreuil, C., Grentzinger, A., Groben, L., Gherissi, D., Guéret, P., Hagege, A., Hammoudi, N., Heliot, F., Henry, P., Herson, S., Houriez, P., Hustache-Mathieu, L., Huttin, O., Imbert, S., Jaureguiberry, S., Kaaki, M., Konate, A., Kuhn, J. M., Kural Menasche, S., Lafitte, A., Lafon, B., Lanternier, F., Le Chenault, V., Lechiche, C., Lefèvre-Thibaut, S., Lefort, A., Leguerrier, A., Lemoine, J., Lepage, L., Lepouse', C., Leroy, J., Lesprit, P., Letranchant, L., Loisance, D., Loncar, G., Lorentz, C., Mabo, P., Magnin-Poull, I., May, T., Makinson, A., Man, H., Mansouri, M., Marxcon, O., Maroni, J. P., Masse, V., Maurier, F., Meyohas, M. C., Michel, P. L., Michelet, C., Mechaï, F., Merceron, O., Messika-Zeitoun, D., Metref, Z., Meyssonnier, V., Mezher, C., Micheli, S., Monsigny, M., Mouly, S., Mourvillier, B., Nallet, O., Noel, V., Papo, T., Payet, B., Pelletier, A., Perez, P., Petit, J. S., Philippart, F., Piet, E., Plainvert, C., Popovic, B., Porte, J. M., Pradier, P., Ramadan, R., Richemond, J., Rodermann, M., Roncato, M., Roigt, I., Ruyer, O., Saada, M., Schwartz, J., Simon, M., Simorre, B., Skalli, S., Spatz, F., Sudrial, J., Tartiere, L., Terrier De La Chaise, A., Thiercelin, M. C., Thomas, D., Thomas, M., Toko, L., Tournoux, F., Tristan, A., Trouillet, J. L., Tual, L., Vahanian, A., Verdier, F., Vernet Garnier, V., vidal, valentina, Weyne, P., Wolff, M., Wynckel, A., Zannad, N., Zinzius, P. Y., University hospital of Trieste, Marqueurs pronostiques et facteurs de régulations des pathologies cardiaques et vasculaires - UFC ( UR 3920) (PCVP / CARDIO), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Hôpital Louis Pradel [CHU - HCL], Hospices Civils de Lyon (HCL), Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), CIC Bichat (CIC1425), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM), DHU FIRE Centre de compétence des maladies pulmonaires rares, Service de cardiologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Maladies chroniques, santé perçue, et processus d'adaptation (APEMAC), Université de Lorraine (UL), Service des maladies infectieuses et tropicales, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu [Nancy], Service de Cardiologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Service des Maladies Infectieuses et Tropicales [Point-à-Pitre, Guadeloupe], CHU Pointe-à-Pitre/Abymes [Guadeloupe], Service des maladies infectieuses et réanimation médicale [Rennes] = Infectious Disease and Intensive Care [Rennes], CHU Pontchaillou [Rennes], Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques et émergentes (TransVIHMI), Institut de Recherche pour le Développement (IRD)-Université de Yaoundé I-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Dr Duval reports grants from Pfizer Inc (New York, NY) outside the submitted work, Association for the Study and Prevention of Infective Endocarditis Study Group–Association pour l’ Etude et la Prevention de l’Endocadite Infectieuse, Modèles et méthodes de l'évaluation thérapeutique des maladies chroniques (U738 / UMR_S738), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris Diderot - Paris 7 (UPD7)-AP-HP - Hôpital Bichat - Claude Bernard [Paris]-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Département de Santé Publique [Paris], Institut de recherche en santé publique [Paris], Laboratoire Chrono-environnement - UFC (UMR 6249) (LCE), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)-Hôpital Saint-Jacques, Centre Michel de Boüard - Centre de recherches archéologiques et historiques anciennes et médiévales (CRAHAM), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-Centre National de la Recherche Scientifique (CNRS), Recherches Translationnelles sur le VIH et les maladies infectieuses (TransVIHMI), Université Montpellier 1 (UM1)-Institut de Recherche pour le Développement (IRD)-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Universtié Yaoundé 1 [Cameroun]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Marqueurs pronostiques et facteurs de régulations des pathologies cardiaques et vasculaires - UFC ( EA 3920) (PCVP / CARDIO), Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)-Université de Franche-Comté (UFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)-Hôpital Jean Minjoz, Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Recherche pour le Développement (IRD)-Université Montpellier 1 (UM1)-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Universtié Yaoundé 1 [Cameroun]-Université de Montpellier (UM), Centre d'Investigation Clinique Antilles Guyane, Inserm CIC1424, Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques er émergentes (TransVIHMI), Modèles et méthodes de l'évaluation thérapeutique des maladies chroniques, Gatti, Giuseppe, Perrotti, Andrea, Obadia, Jean-Françoi, Duval, Xavier, Iung, Bernard, Alla, Françoi, Chirouze, Catherine, Selton-Suty, Christine, Hoen, Bruno, Sinagra, Gianfranco, Delahaye, Françoi, Tattevin, Pierre, Le Moing, Vincent, Pappalardo, Aniello, Chocron, Sidney, Hoen, B., Duval, X., Alla, F., Bouvet, A., Briancon, S., Cambau, E., Celard, M., Chirouze, C., Danchin, N., Doco-Lecompte, T., Delahaye, F., Etienne, J., Iung, B., Le Moing, V., Obadia, J. F., Leport, C., Poyart, C., Revest, M., Selton-Suty, C., Strady, C., Tattevin, P., Vandenesch, F., Bernard, Y., Chocron, S., Plesiat, P., Abouliatim, I., De Place, C., Donnio, P. Y., Carteaux, J. P., Lion, C., Aissa, N., Baehrel, B., Jaussaud, R., Nazeyrollas, P., Vernet, V., Nataf, P., Chidiac, C., Aumaître, H., Frappier, J. M., Oziol, E., Sotto, A., Sportouch, C., Bes, M., Abassade, P., Abrial, E., Acar, C., Alexandra, J. F., Amireche, N., Amrein, D., Andre, P., Appriou, M., Arnould, M. A., Assayag, P., Atoui, A., Aziza, F., Baille, N., Bajolle, N., Battistella, P., Baumard, S., Ben Ali, A., Bertrand, J., Bialek, S., Bois Grosse, M., Boixados, M., Borlot, F., Bouchachi, A., Bouche, O., Bouchemal, S., Bourdon, J. L., Brasme, L., Bricaire, F., Brochet, E., Bruntz, J. F., Cady, A., Cailhol, J., Caplan, M. P., Carette, B., Cartry, O., Cazorla, C., Chamagne, H., Champagne, H., Chanques, G., Chastre, J., Chevalier, B., Chometon, F., Christophe, C., Cohen, A., Colin de Verdiere, N., Daneluzzi, Valeria, David, L., De Lentdecker, P., Delcey, V., Deleuze, P., Donal, E., Deroure, B., Descotes-Genon, V., Didier Petit, K., Dinh, A., Doat, V., Duchene, F., Duhoux, F., Dupont, M., Ederhy, S., Epaulard, O., Evest, M., Faucher, J. F., Fantin, Barbara, Fauveau, E., Ferry, T., Fillod, M., Floch, T., Fraisse, T., Frapier, J. M., Freysz, L., Fumery, B., Gachot, B., Gallien, S., Gandjbach, I., Garcon, P., Gaubert, A., Genoud, J. L., Ghiglione, S., Godreuil, C., Grentzinger, A., Groben, L., Gherissi, D., Guéret, P., Hagege, A., Hammoudi, N., Heliot, F., Henry, P., Herson, S., Houriez, P., Hustache-Mathieu, L., Huttin, O., Imbert, S., Jaureguiberry, S., Kaaki, M., Konate, A., Kuhn, J. M., Kural Menasche, S., Lafitte, A., Lafon, B., Lanternier, F., Le Chenault, V., Lechiche, C., Lefèvre-Thibaut, S., Lefort, A., Leguerrier, A., Lemoine, J., Lepage, L., Lepouse', C., Leroy, J., Lesprit, P., Letranchant, L., Loisance, D., Loncar, G., Lorentz, C., Mabo, P., Magnin-Poull, I., May, T., Makinson, A., Man, H., Mansouri, M., Marxcon, O., Maroni, J. P., Masse, V., Maurier, F., Meyohas, M. C., Michel, P. L., Michelet, C., Mechaï, F., Merceron, O., Messika-Zeitoun, D., Metref, Z., Meyssonnier, V., Mezher, C., Micheli, S., Monsigny, M., Mouly, S., Mourvillier, B., Nallet, O., Noel, V., Papo, T., Payet, B., Pelletier, A., Perez, P., Petit, J. S., Philippart, F., Piet, E., Plainvert, C., Popovic, B., Porte, J. M., Pradier, P., Ramadan, R., Richemond, J., Rodermann, M., Roncato, M., Roigt, I., Ruyer, O., Saada, M., Schwartz, J., Simon, M., Simorre, B., Skalli, S., Spatz, F., Sudrial, J., Tartiere, L., Terrier De La Chaise, A., Thiercelin, M. C., Thomas, D., Thomas, M., Toko, L., Tournoux, F., Tristan, A., Trouillet, J. L., Tual, L., Vahanian, A., Verdier, F., Vernet Garnier, V., Vidal, Valentina, Weyne, P., Wolff, M., Wynckel, A., Zannad, N., Zinzius, P. Y., Marqueurs pronostiques et facteurs de régulations des pathologies cardiaques et vasculaires - UFC ( PCVP / CARDIO ), Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ) -Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ), Hospices Civils de Lyon ( HCL ), Infection, Antimicrobiens, Modélisation, Evolution ( IAME ), Université Paris Diderot - Paris 7 ( UPD7 ) -Université Paris 13 ( UP13 ) -Université Sorbonne Paris Cité ( USPC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), CIC Bichat ( CIC1425 ), Assistance publique - Hôpitaux de Paris (AP-HP)-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Assistance publique - Hôpitaux de Paris (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Risques, maladies chroniques et société : des systèmes biologiques aux populations, Université Henri Poincaré - Nancy 1 ( UHP ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Jean Minjoz, Centre Hospitalier Régional Universitaire de Nancy ( CHRU Nancy ), Recherches Translationnelles sur le VIH et les maladies infectieuses ( TransVIHMI ), Université Montpellier 1 ( UM1 ) -Université Cheikh Anta Diop ( UCAD ) -Universtié Yaoundé 1 (Cameroun)-Université de Montpellier ( UM ), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), and Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Institut de Recherche pour le Développement (IRD)-Université de Yaoundé I-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Université Montpellier 1 (UM1)
- Subjects
Male ,Time Factors ,[SDV]Life Sciences [q-bio] ,Infective endocarditi ,030204 cardiovascular system & hematology ,Logistic regression ,0302 clinical medicine ,Risk Factors ,pulmonary hypertension ,Odds Ratio ,Cardiac valvular surgery ,Hospital Mortality ,Prospective Studies ,030212 general & internal medicine ,Treatment outcome ,ComputingMilieux_MISCELLANEOUS ,Original Research ,Cardiovascular Surgery ,Framingham Risk Score ,Endocarditis ,[ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie ,Middle Aged ,Critical care ,Infective endocarditis ,Mortality ,Predictors ,Pulmonary hypertension ,Quality control ,Cardiology and Cardiovascular Medicine ,Cardiac surgery ,Europe ,Treatment Outcome ,Area Under Curve ,Female ,Mortality/Survival ,medicine.medical_specialty ,Renal function ,Risk Assessment ,Decision Support Techniques ,03 medical and health sciences ,Predictive Value of Tests ,medicine ,Humans ,Infectious Endocarditis ,quality control ,Cardiac Surgical Procedures ,Risk factor ,Aged ,Chi-Square Distribution ,Receiver operating characteristic ,infective endocarditis ,business.industry ,Odds ratio ,cardiac valvular surgery ,medicine.disease ,mortality ,Surgery ,critical care ,predictors ,Logistic Models ,ROC Curve ,[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie ,Valvular Heart Disease ,Multivariate Analysis ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,business ,Predictor - Abstract
Background Aspecific scoring systems are used to predict the risk of death postsurgery in patients with infective endocarditis ( IE ). The purpose of the present study was both to analyze the risk factors for in‐hospital death, which complicates surgery for IE , and to create a mortality risk score based on the results of this analysis. Methods and Results Outcomes of 361 consecutive patients (mean age, 59.1±15.4 years) who had undergone surgery for IE in 8 European centers of cardiac surgery were recorded prospectively, and a risk factor analysis (multivariable logistic regression) for in‐hospital death was performed. The discriminatory power of a new predictive scoring system was assessed with the receiver operating characteristic curve analysis. Score validation procedures were carried out. Fifty‐six (15.5%) patients died postsurgery. BMI >27 kg/m 2 (odds ratio [ OR ], 1.79; P =0.049), estimated glomerular filtration rate OR , 3.52; P IV ( OR , 2.11; P =0.024), systolic pulmonary artery pressure >55 mm Hg ( OR , 1.78; P =0.032), and critical state ( OR , 2.37; P =0.017) were independent predictors of in‐hospital death. A scoring system was devised to predict in‐hospital death postsurgery for IE (area under the receiver operating characteristic curve, 0.780; 95% CI, 0.734–0.822). The score performed better than 5 of 6 scoring systems for in‐hospital death after cardiac surgery that were considered. Conclusions A simple scoring system based on risk factors for in‐hospital death was specifically created to predict mortality risk postsurgery in patients with IE .
- Published
- 2017
- Full Text
- View/download PDF
18. Unexpected mould diversity in clinical isolates from French Guiana and associated identification difficulties.
- Author
-
Nabet, C, Imbert, S, Normand, A C, Blanchet, D, Chanlin, R, Becker, P, Demar, M, and Piarroux, R
- Abstract
New mold species are increasingly reported in invasive fungal infections. However, these fungi are often misdiagnosed or undiagnosed due to the use of inappropriate laboratory diagnostic tools. Tropical countries, such as French Guiana, harbor a vast diversity of environmental fungi representing a potential source of emerging pathogens. To assess the impact of this diversity on the accuracy of mold-infection diagnoses, we identified mold clinical isolates in French Guiana during a five-month follow-up using both microscopy and matrix-assisted laser desorption ionization time-of-flight mass spectrometry. In total, 38.8% of the 98 obtained molds isolates could not be identified and required a DNA-based identification. Fungal diversity was high, including 46 species, 26 genera, and 13 orders. Fungal ecology was unusual, as Aspergillus species accounted for only 27% of all isolates, and the Nigri section was the most abundant out of the six detected Aspergillus sections. Macromycetes (orders Agaricales, Polyporales , and Russulales) and endophytic fungi accounted for respectively 11% and 14% of all isolates. Thus, in tropical areas with high fungal diversity, such as French Guiana, routine mold identification tools are inadequate. Molecular identifications, as well as morphological descriptions, are necessary for the construction of region-specific mass spectrum databases. These advances will improve the diagnosis and clinical management of new fungal infections. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
19. Predicting in silico the Direct-Peptide-Reactivity-Assay (DPRA) within the Allergic Contact Dermatitis framework: A module accounting for test variability and abiotic transformations
- Author
-
Detroyer, A., primary, Ivanova, H., additional, Eilstein, J., additional, Piroird, C., additional, Imbert, S., additional, Del Bufalo, A., additional, Popova, I., additional, Kuseva, C., additional, Karakolev, I., additional, Dimitrov, S., additional, and Mekenyan, O., additional
- Published
- 2018
- Full Text
- View/download PDF
20. Species Identification and In Vitro Antifungal Susceptibility of Aspergillus terreus Species Complex Clinical Isolates from a French Multicenter Study
- Author
-
Imbert, S., primary, Normand, A. C., additional, Ranque, S., additional, Costa, J. M., additional, Guitard, J., additional, Accoceberry, I., additional, Bonnal, C., additional, Fekkar, A., additional, Bourgeois, N., additional, Houzé, S., additional, Hennequin, C., additional, Piarroux, R., additional, Dannaoui, E., additional, and Botterel, F., additional
- Published
- 2018
- Full Text
- View/download PDF
21. Direct fibrosis markers kinetic in patients undergoing antiviral treatment with DAA for chronic hepatitis C
- Author
-
Mazzarelli, C., primary, Bruce, M., additional, Imbert, S., additional, Cannon, M.D., additional, Dusheiko, G., additional, Agarwal, K., additional, and Carey, I., additional
- Published
- 2018
- Full Text
- View/download PDF
22. Which pregnancy biomarkers predict post-delivery ALT flares in mothers with chronic hepatitis B?
- Author
-
Imbert, S., primary, Bruce, M., additional, Montague, S., additional, Mcleod, M.-A., additional, Bowyer, T., additional, Horner, M., additional, Dusheiko, G., additional, Agarwal, K., additional, and Carey, I., additional
- Published
- 2018
- Full Text
- View/download PDF
23. Performance of Aspergillus PCR in cerebrospinal fluid for the diagnosis of cerebral aspergillosis
- Author
-
Imbert, S., primary, Brossas, J.-Y., additional, Palous, M., additional, Joly, I., additional, Meyer, I., additional, and Fekkar, A., additional
- Published
- 2017
- Full Text
- View/download PDF
24. Predicting in silico the Direct-Peptide-Reactivity-Assay (DPRA) within the Allergic Contact Dermatitis framework
- Author
-
Detroyer, Ann, primary, Piroird, C., additional, Eilstein, J., additional, Imbert, S., additional, Ivanova, H., additional, Popova, I., additional, Kuseva, C., additional, Karakolev, Y., additional, Dimitrov, S., additional, and Mekenyan, Ovanes, additional
- Published
- 2017
- Full Text
- View/download PDF
25. Usages et apprentissages par les technologies : quand l’écart générationnel mène au désordre et à de nouvelles opportunités
- Author
-
Chollet, Aurélien, Imbert, S., Montpellier Research in Management (MRM), Université Montpellier 1 (UM1)-Université Paul-Valéry - Montpellier 3 (UPVM)-Université Montpellier 2 - Sciences et Techniques (UM2)-Université de Perpignan Via Domitia (UPVD)-Groupe Sup de Co Montpellier (GSCM) - Montpellier Business School-Université de Montpellier (UM), and Université Paul-Valéry - Montpellier 3 (UPVM)-Université de Perpignan Via Domitia (UPVD)-Groupe Sup de Co Montpellier (GSCM) - Montpellier Business School-Université de Montpellier (UM)
- Subjects
[SHS.GESTION]Humanities and Social Sciences/Business administration ,[INFO.EIAH]Computer Science [cs]/Technology for Human Learning ,ComputingMilieux_MISCELLANEOUS - Abstract
International audience
- Published
- 2015
26. Interpretation of the Elecsys Toxo IgG avidity results for very low and very high index: study on 741 sera with a determined date of toxoplasmosis
- Author
-
Fricker-Hidalgo, H., primary, L’Ollivier, C., additional, Bosson, C., additional, Imbert, S., additional, Bailly, S., additional, Dard, C., additional, Piarroux, R., additional, Paris, L., additional, and Pelloux, H., additional
- Published
- 2016
- Full Text
- View/download PDF
27. Discontinuation of echinocandin and azole treatments led to the disappearance of an FKS alteration but not azole resistance during clonal Candida glabrata persistent candidaemia
- Author
-
Imbert, S., primary, Castain, L., additional, Pons, A., additional, Jacob, S., additional, Meyer, I., additional, Palous, M., additional, Vezinet, C., additional, Langeron, O., additional, Hennequin, C., additional, Monsel, A., additional, and Fekkar, A., additional
- Published
- 2016
- Full Text
- View/download PDF
28. Argument clinique pour l’existence d’un fitness cost lié à la résistance de Candida glabrata aux échinocandines
- Author
-
Fekkar, A., primary, Castain, L., additional, Pons, A., additional, Meyer, I., additional, Palous, M., additional, Vezinet, C., additional, Mazier, D., additional, Langeron, O., additional, Hennequin, C., additional, Monsel, A., additional, and Imbert, S., additional
- Published
- 2016
- Full Text
- View/download PDF
29. FRI-317 - Which pregnancy biomarkers predict post-delivery ALT flares in mothers with chronic hepatitis B?
- Author
-
Imbert, S., Bruce, M., Montague, S., Mcleod, M.-A., Bowyer, T., Horner, M., Dusheiko, G., Agarwal, K., and Carey, I.
- Published
- 2018
- Full Text
- View/download PDF
30. FRI-093 - Direct fibrosis markers kinetic in patients undergoing antiviral treatment with DAA for chronic hepatitis C
- Author
-
Mazzarelli, C., Bruce, M., Imbert, S., Cannon, M.D., Dusheiko, G., Agarwal, K., and Carey, I.
- Published
- 2018
- Full Text
- View/download PDF
31. Étude des réponses fonctionnelles du polynucléaire neutrophile vis-à-vis d’ Aspergillus fumigatus chez le patient allogreffé de moelle osseuse
- Author
-
Imbert, S., primary, Gauthier, L., additional, Panellier, C., additional, Miranda, N., additional, Leblond, V., additional, Mazier, D., additional, N’Guyen, S., additional, and Fekkar, A., additional
- Published
- 2015
- Full Text
- View/download PDF
32. In Vitro Combination of Voriconazole and Miltefosine against Clinically Relevant Molds
- Author
-
Imbert, S., primary, Palous, M., additional, Meyer, I., additional, Dannaoui, E., additional, Mazier, D., additional, Datry, A., additional, and Fekkar, A., additional
- Published
- 2014
- Full Text
- View/download PDF
33. Étude des réponses fonctionnelles du polynucléaire neutrophile vis-à-vis d’Aspergillus fumigatus chez le patient allogreffé de moelle osseuse
- Author
-
Imbert, S., Gauthier, L., Panellier, C., Miranda, N., Leblond, V., Mazier, D., N’Guyen, S., and Fekkar, A.
- Published
- 2015
- Full Text
- View/download PDF
34. Development of a mechanistic QSAR model for the detection of phototoxic chemicals and use in an integrated testing strategy
- Author
-
Ringeissen, S., primary, Marrot, L., additional, Note, R., additional, Labarussiat, A., additional, Imbert, S., additional, Todorov, M., additional, Mekenyan, O., additional, and Meunier, J.R., additional
- Published
- 2010
- Full Text
- View/download PDF
35. In VitroCombination of Voriconazole and Miltefosine against Clinically Relevant Molds
- Author
-
Imbert, S., Palous, M., Meyer, I., Dannaoui, E., Mazier, D., Datry, A., and Fekkar, A.
- Abstract
ABSTRACTInvasive infections caused by filamentous fungi are a major threat for immunocompromised patients. Innate/acquired resistance to antifungal drugs might necessitate combination therapies. We assessed the potential combination of voriconazole with miltefosine, an original drug with antifungal activity against 33 clinically relevant mold isolates, including both azole-susceptible and -resistant Aspergillus. Using complete inhibition as an endpoint, interactions were indifferent for 32/33 isolates. An alternative 50% inhibition endpoint showed synergistic interactions for 14/33 isolates. Antagonism was absent.
- Published
- 2014
- Full Text
- View/download PDF
36. Multicentric Analysis of the Species Distribution and Antifungal Susceptibility of Cryptic Isolates from AspergillusSection Fumigati
- Author
-
Imbert, S., Normand, A. C., Cassaing, S., Gabriel, F., Kristensen, L., Bonnal, C., Lachaud, L., Costa, D., Guitard, J., Hasseine, L., Palous, M., Piarroux, M., Hendrickx, M., Piarroux, R., and Fekkar, A.
- Abstract
The antifungal susceptibility of Aspergilluscryptic species is poorly known. We assessed 51 isolates, belonging to seven Fumigaticryptic species, by the EUCAST reference method and the concentration gradient strip (CGS) method. Species-specific patterns were observed, with high MICs for azole drugs, except for Aspergillus hiratsukaeand Aspergillus tsurutae, and high MICs for amphotericin B for Aspergillus lentulusand Aspergillus udagawae.
- Published
- 2020
- Full Text
- View/download PDF
37. Species Distribution and Comparison between EUCAST and Gradient Concentration Strips Methods for Antifungal Susceptibility Testing of 112 AspergillusSection NigriIsolates
- Author
-
Carrara, B., Richards, R., Imbert, S., Morio, F., Sasso, M., Zahr, N., Normand, A. C., Le Pape, P., Lachaud, L., Ranque, S., Maubon, D., Piarroux, R., and Fekkar, A.
- Abstract
Aspergillus niger, the third species responsible for invasive aspergillosis, has been considered as a homogeneous species until DNA-based identification uncovered many cryptic species. These species have been recently reclassified into the Aspergillussection Nigri. However, little is yet known among the section Nigriabout the species distribution and the antifungal susceptibility pattern of each cryptic species. A total of 112 clinical isolates collected from 5 teaching hospitals in France and phenotypically identified as A. nigerwere analyzed.
- Published
- 2020
- Full Text
- View/download PDF
38. Précis du code de la route : tous les décrets parus à ce jour, commentaires pratiques à l'usage des automobilistes, piétons, hommes d'affaires et agents chargés d'assurer la police de la route / S. Imbert,...
- Author
-
Imbert, S.. Auteur du texte and Imbert, S.. Auteur du texte
- Abstract
Contient une table des matières, Avec mode texte
- Published
- 1938
39. Consistency analysis in a hierarchical production planning system
- Author
-
Fontan, G., primary, Imbert, S., additional, and Merce, C., additional
- Published
- 1985
- Full Text
- View/download PDF
40. The impact of lowering the cut-off value on the sensitivity of the Platelia Elisa IgG (Bio-Rad) test for toxoplasmosis diagnosis
- Author
-
Mouri Oussama, Kendjo Eric, Touafek Feriel, Fekkar Arnaud, Konte Ousmane, Imbert Sebastien, Courtin Régis, Mazier Dominique, and Paris Luc
- Subjects
Toxoplasmosis ,Toxoplasma gondii ,Congenital toxoplasmosis ,Pregnant women ,Western blot ,Infectious and parasitic diseases ,RC109-216 - Abstract
Determining specific immune status against Toxoplasma gondii is essential for assessing the risk of reactivation in immunocompromised patients or defining serological monitoring and appropriate prophylactic measures during pregnancy. In France, toxoplasmosis serological screening requires systematic testing for IgM and IgG antibodies. The Platelia Toxo IgG and IgM test (Bio-Rad) is one of the most widely used tests for anti-toxoplasmic antibody detection. We performed a study on 384 sera, including 123 IgG negative (
- Published
- 2015
- Full Text
- View/download PDF
41. Species Identification and In VitroAntifungal Susceptibility of Aspergillus terreusSpecies Complex Clinical Isolates from a French Multicenter Study
- Author
-
Imbert, S., Normand, A. C., Ranque, S., Costa, J. M., Guitard, J., Accoceberry, I., Bonnal, C., Fekkar, A., Bourgeois, N., Houzé, S., Hennequin, C., Piarroux, R., Dannaoui, E., and Botterel, F.
- Abstract
ABSTRACTAspergillussection Terreiis a species complex currently comprised of 14 cryptic species whose prevalence in clinical samples as well as antifungal susceptibility are poorly known. The aims of this study were to investigate A. Terreiclinical isolates at the species level and to perform antifungal susceptibility analyses by reference and commercial methods. Eighty-two clinical A. Terreiisolates were collected from 8 French university hospitals. Molecular identification was performed by sequencing parts of beta-tubulin and calmodulin genes. MICs or minimum effective concentrations (MECs) were determined for 8 antifungal drugs using both EUCAST broth microdilution (BMD) methods and concentration gradient strips (CGS). Among the 79 A. Terreiisolates, A. terreus stricto sensu(n= 61), A. citrinoterreus(n= 13), A. hortai(n= 3), and A. alabamensis(n= 2) were identified. All strains had MICs of ≥1 mg/liter for amphotericin B, except for two isolates (both A. hortai) that had MICs of 0.25 mg/liter. Four A. terreusisolates were resistant to at least one azole drug, including one with pan-azole resistance, yet no mutation in the CYP51Agene was found. All strains had low MECs for the three echinocandins. The essential agreements (EAs) between BMD and CGS were >90%, except for those of amphotericin B (79.7%) and itraconazole (73.4%). Isolates belonging to the A. section Terreiidentified in clinical samples show wider species diversity beyond the known A. terreus sensu stricto. Azole resistance inside the section Terreiis uncommon and is not related to CYP51A mutations here. Finally, CGS is an interesting alternative for routine antifungal susceptibility testing.
- Published
- 2018
- Full Text
- View/download PDF
42. Utility of Mucorales polymerase chain reaction to diagnose Rhizomucor infections in neutropenic patients.
- Author
-
Pfister E, Brousse X, Blanchard E, Issa N, Gabriel F, Jubert C, Kaminski H, Forcade E, Dumas PY, Delhaes L, Lefranc M, and Imbert S
- Subjects
- Humans, Retrospective Studies, Male, Female, Middle Aged, Adult, Aged, DNA, Fungal genetics, Young Adult, Mucormycosis diagnosis, Mucormycosis microbiology, Mucormycosis epidemiology, Rhizomucor genetics, Polymerase Chain Reaction methods, Neutropenia complications, Mucorales isolation & purification, Mucorales genetics, Mucorales classification
- Abstract
Mucormycoses are life-threatening infections related to fungi from the Mucorales order. Based on fungal culture, the most frequently involved genera are Rhizopus spp., Mucor spp., or Lichtheimia spp. However, since the introduction of Mucorales polymerase chain reaction (PCR), many diagnoses have been made without positive fungal culture, biasing mucormycosis epidemiology. We conducted a single-centre retrospective observational study on invasive mucormycosis cases diagnosed between April 2020 and December 2022. Cases were classified according to EORTC/MSGERC definitions, adding a 'PCR-only' category for patients with a positive Mucorales PCR as the only mycological evidence. Genus/species identification was obtained by sequencing the Mucorales 18S rDNA directly on Mucorales PCR-positive samples. We identified 35 cases of mucormycosis, including 6 proven, 7 probable, and 22 'PCR-only'. Genus/species identification was achievable in 34 cases and surprisingly revealed the genus Rhizomucor as the main aetiological agent (n = 14, 41.2%). Interestingly, all the Rhizomucor infections, except one, were classified as 'PCR-only', while fungal culture was positive in 11/20 (55%) for other Mucorales genera (P <.001). Moreover, in comparison with other genera, the genus Rhizomucor was significantly more associated with neutropenia (11/14 [78.6%] vs. 2/20 [10%], P < .0001) and pulmonary localizations (11/14 [78.6%] vs. 6/20 [30%], P = .01). Our study reveals the changing epidemiology of mucormycosis in our centre with the use of Mucorales PCR and underlines the importance of the genus Rhizomucor, especially in neutropenic patients. This highlights the benefits of using Mucorales PCR in clinical practice for mucormycosis diagnosis in high-risk patients and the need to include it in diagnostic criteria., (© The Author(s) 2025. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology.)
- Published
- 2025
- Full Text
- View/download PDF
43. Laboratory practices for the diagnosis and management of mucormycosis in France, 2024.
- Author
-
Millon L, Botterel F, Bonhomme J, Valot S, Poirier P, Durieux MF, Bigot J, Desoubeaux G, Chesnais A, Morio F, Pihet M, Brunet K, Bellanger AP, Imbert S, Nevez G, Gal SL, Bourgeois N, Debourgogne A, Cornu M, Persat F, Hasseine L, Bougnoux ME, Brun S, Cornet M, Favennec L, Gargala G, Bonnal C, Gangneux JP, Alanio A, Iriart X, Mahinc C, Chouaki T, Paugam A, Letscher-Bru V, and Dannaoui E
- Subjects
- Humans, France epidemiology, Triazoles therapeutic use, Amphotericin B therapeutic use, Laboratories, Hospital, Hospitals, University, Laboratories standards, Clinical Laboratory Techniques standards, Clinical Laboratory Techniques methods, Nitriles, Pyridines, Mucormycosis diagnosis, Mucormycosis drug therapy, Mucormycosis epidemiology, Mucormycosis microbiology, Mucormycosis therapy, Antifungal Agents therapeutic use, Mucorales isolation & purification, Mucorales drug effects, Microbial Sensitivity Tests
- Abstract
This study investigates the diagnostic practices for mucormycosis among 30 French University Hospital mycology laboratories, in 2024. All laboratories perform both direct examination and culture, with fluorescent brighteners being the most commonly used method for direct examination. While 77 % of the participating laboratories routinely identify Mucorales to the species level, with 70 % having adopted Mucorales-specific quantitative PCR, primarily for the diagnosis of invasive fungal infections. Antifungal susceptibility testing practices varied between centers, with 36.7 % of laboratories consistently performing these tests, primarily using gradient concentration strips. Amphotericin B, posaconazole, and isavuconazole were the most frequently tested antifungals. These findings highlight variations in laboratory practices and emphasize the importance of establishing uniform diagnostic and susceptibility testing methods to optimize mucormycosis management., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Eric Dannaoui has received research grants from Biomérieux: travel grants from Gilead, Mundipharma, and Pfizer; speaker's fee from Mundipharma, Pfizer, and Gilead. Kévin Brunet has received travel grants from Pfizer and Gilead and speaker's fee from Gilead. Laurence Millon has received travel grants from Gilead and Pfizer; speaker's fee from Gilead and Pfizer. Marjorie Cornu received travel grants and speaker's fee from Gilead and Pfizer. The other authors have no conflicts of interest to disclose., (Copyright © 2024 SFMM. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
44. Autochthonous Trichophyton rubrum terbinafine resistance in France: assessment of antifungal susceptibility tests.
- Author
-
Moreno-Sabater A, Cordier C, Normand AC, Bidaud AL, Cremer G, Bouchara JP, Huguenin A, Imbert S, Challende I, Brin C, Foulet F, Sendid B, Laloum I, Magne D, Hennequin C, Monod M, Desoubeaux G, and Dannaoui É
- Published
- 2024
- Full Text
- View/download PDF
45. Is there still a place for serum galactomannan in the diagnosis of invasive aspergillosis in children at high risk and under antifungal prophylaxis?
- Author
-
Gerard R, Gabriel F, Accoceberry I, Imbert S, Ducassou S, Angoso M, and Jubert C
- Subjects
- Humans, Retrospective Studies, Child, Male, Female, Child, Preschool, Adolescent, Infant, Invasive Pulmonary Aspergillosis diagnosis, Invasive Pulmonary Aspergillosis prevention & control, Aspergillosis diagnosis, Aspergillosis prevention & control, Aspergillosis blood, Sensitivity and Specificity, Predictive Value of Tests, Mannans blood, Galactose analogs & derivatives, Antifungal Agents therapeutic use
- Abstract
Background: The performance of serum galactomannan (GM) for the diagnosis of invasive aspergillosis (IA) has been studied mainly in adults. Paediatric data are scarce and based on small and heterogeneous cohorts., Objective: To evaluate the performance of serum GM for the diagnosis of IA in a paediatric oncologic population at high risk of IA and to clarify the impact of antifungal prophylaxis on this test., Methods: We performed a retrospective study from January 2014 to December 2020 in the paediatric oncologic haematologic department of the University Hospital of Bordeaux. The diagnosis of IA was made using the recommendations of the EORTC and the MSGERC., Results: Among the 329 periods at high risk of IA in 222 patients, the prevalence of IA was 1.8% (3 proven and 3 probable IA). In the total population, the sensitivity, and the positive predictive value (PPV) were respectively 50% and 17.6%. Under antifungal prophylaxis, the sensitivity and PPV dropped, respectively, to 33.3% and 14.3%. In this group, the post-test probability of IA was 2% for a negative serum GM and only 14%., Conclusion: In this large cohort of children at high risk of IA, the incidence of IA is low and the diagnostic performance of GM is poor, especially in the case of mould-active prophylaxis. Screening should be targeted rather than systematic and should be reserved for patients at highest risk for IA without mould-active prophylaxis. Combination with other tests such as Aspergillus PCR would increase the accuracy of GM in screening setting., (© 2024 The Author(s). Mycoses published by Wiley‐VCH GmbH.)
- Published
- 2024
- Full Text
- View/download PDF
46. Sampling and processing matter in airway microbiota discovery.
- Author
-
Imbert S, Revers M, Enaud R, Orieux A, Delhaes L, and Prével R
- Subjects
- Humans, Specimen Handling methods, Specimen Handling standards, Respiratory System microbiology, Microbiota physiology
- Published
- 2024
- Full Text
- View/download PDF
47. Lower airway microbiota compositions differ between influenza, COVID-19 and bacteria-related acute respiratory distress syndromes.
- Author
-
Imbert S, Revers M, Enaud R, Orieux A, Camino A, Massri A, Villeneuve L, Carrié C, Petit L, Boyer A, Berger P, Gruson D, Delhaes L, and Prével R
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Bacterial Infections microbiology, COVID-19 microbiology, COVID-19 complications, COVID-19 physiopathology, Respiratory Distress Syndrome microbiology, Respiratory Distress Syndrome virology, Respiratory Distress Syndrome physiopathology, Influenza, Human microbiology, Influenza, Human physiopathology, Influenza, Human complications, Microbiota physiology
- Abstract
Background: Acute respiratory distress syndrome (ARDS) is responsible for 400,000 deaths annually worldwide. Few improvements have been made despite five decades of research, partially because ARDS is a highly heterogeneous syndrome including various types of aetiologies. Lower airway microbiota is involved in chronic inflammatory diseases and recent data suggest that it could also play a role in ARDS. Nevertheless, whether the lower airway microbiota composition varies between the aetiologies of ARDS remain unknown. The aim of this study is to compare lower airway microbiota composition between ARDS aetiologies, i.e. pulmonary ARDS due to influenza, SARS-CoV-2 or bacterial infection., Methods: Consecutive ARDS patients according to Berlin's classification requiring invasive ventilation with PCR-confirmed influenza or SARS-CoV-2 infections and bacterial infections (> 105 CFU/mL on endotracheal aspirate) were included. Endotracheal aspirate was collected at admission, V3-V4 and ITS2 regions amplified by PCR, deep-sequencing performed on MiSeq sequencer (Illumina®) and data analysed using DADA2 pipeline., Results: Fifty-three patients were included, 24 COVID-19, 18 influenza, and 11 bacterial CAP-related ARDS. The lower airway bacteriobiota and mycobiota compositions (β-diversity) were dissimilar between the three groups (p = 0.05 and p = 0.01, respectively). The bacterial α-diversity was significantly lower in the bacterial CAP-related ARDS group compared to the COVID-19 ARDS group (p = 0.04). In contrast, influenza-related ARDS patients had higher lung mycobiota α-diversity than the COVID-19-related ARDS (p = 0 < 01)., Conclusion: Composition of lower airway microbiota (both microbiota and mycobiota) differs between influenza, COVID-19 and bacterial CAP-related ARDS. Future studies investigating the role of lung microbiota in ARDS pathophysiology should take aetiology into account., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
48. Performance of Mucorales spp. qPCR in bronchoalveolar lavage fluid for the diagnosis of pulmonary mucormycosis.
- Author
-
Brousse X, Imbert S, Issa N, Forcade E, Faure M, Chambord J, Ramaroson H, Kaminski H, Dumas PY, and Blanchard E
- Subjects
- Humans, Bronchoalveolar Lavage Fluid, Retrospective Studies, Polymerase Chain Reaction veterinary, DNA, Fungal, Sensitivity and Specificity, Mucorales genetics, Mucormycosis diagnosis, Mucormycosis veterinary
- Abstract
To estimate the diagnostic performance of Mucorales polymerase chain reaction (PCR) in Bronchoalveolar lavage fluid (BALF) in routine practice. This was a single-center retrospective study including all consecutive patients >18 years who underwent Mucorales PCR assay in BALF between January 2021 and May 2022. Index testing was prospectively performed using the MycoGENIE Aspergillus spp.-Mucorales spp. PCR. The reference was the diagnosis of pulmonary mucormycosis by the Adjudication Committee. Mucorales PCR in BALF was performed for 938 patients and was positive for 21 of 938 (2.2%). Eleven pulmonary mucormycosis (including one disseminated) were diagnosed. Among them, one (9.1%) was classified as proven mucormycosis, three (27.3%) as probable, and seven (63.6%) as possible according to the EORTC/MSGERC 2019 criteria. The main host factor was hematological malignancy (10 of 11, 90.9%). Mucorales PCR was positive in serum for eight patients (72.7%). Three patients had positive PCR in BALF, but negative in serum. The mean cycle threshold value was significantly lower in mucormycosis than false-positive cases. Sensitivity was 72.7% (95% confidence interval [CI], 43.4-90.3%), and specificity was 98.6% (95% CI, 97.6-99.2%). The positive and negative predictive values were 38.1% (95% CI, 20.8-59.1%) and 99.7% (95% CI, 99.1-99.9%), respectively. Mucorales PCR in BALF showed good diagnostic performance for mucormycosis, particularly in combination with serum PCR. A positive result should be interpreted with caution, given the possibility of carriage in the airway. However, its high negative predictive value and specificity suggest the utility of Mucorales PCR in BALF in the diagnosis of pulmonary mucormycosis., (© The Author(s) 2024. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology.)
- Published
- 2024
- Full Text
- View/download PDF
49. The gut-lung axis in the CFTR modulator era.
- Author
-
Lussac-Sorton F, Charpentier É, Imbert S, Lefranc M, Bui S, Fayon M, Berger P, Enaud R, and Delhaes L
- Subjects
- Humans, Bacteria, Cystic Fibrosis Transmembrane Conductance Regulator genetics, Lung, Cystic Fibrosis drug therapy, Microbiota, Dysbiosis microbiology
- Abstract
The advent of CFTR modulators represents a turning point in the history of cystic fibrosis (CF) management, changing profoundly the disease's clinical course by improving mucosal hydration. Assessing changes in airway and digestive tract microbiomes is of great interest to better understand the mechanisms and to predict disease evolution. Bacterial and fungal dysbiosis have been well documented in patients with CF; yet the impact of CFTR modulators on microbial communities has only been partially deciphered to date. In this review, we aim to summarize the current state of knowledge regarding the impact of CFTR modulators on both pulmonary and digestive microbiomes. Our analysis also covers the inter-organ connections between lung and gut communities, in order to highlight the gut-lung axis involvement in CF pathophysiology and its evolution in the era of novel modulators therapies., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Lussac-Sorton, Charpentier, Imbert, Lefranc, Bui, Fayon, Berger, Enaud and Delhaes.)
- Published
- 2023
- Full Text
- View/download PDF
50. The gut microbiota composition is linked to subsequent occurrence of ventilator-associated pneumonia in critically ill patients.
- Author
-
Orieux A, Enaud R, Imbert S, Boyer P, Begot E, Camino A, Boyer A, Berger P, Gruson D, Delhaes L, and Prevel R
- Abstract
Ventilator-associated pneumonia (VAP) is the most frequent nosocomial infection in critically ill-ventilated patients. Oropharyngeal and lung microbiota have been demonstrated to be associated with VAP occurrence, but the involvement of gut microbiota has not been investigated so far. Therefore, the aim of this study is to compare the composition of the gut microbiota between patients who subsequently develop VAP and those who do not. A rectal swab was performed at admission of every consecutive patient into the intensive care unit (ICU) from October 2019 to March 2020. After DNA extraction, V3-V4 and internal transcribed spacer 2 regions deep-sequencing was performed on MiSeq sequencer (Illumina) and data were analyzed using Divisive Amplicon Denoising Algorithm 2 (DADA2) pipeline. Among 255 patients screened, 42 (16%) patients with invasive mechanical ventilation for more than 48 h were included, 18 (43%) with definite VAP and 24 without (57%). Patients who later developed VAP had similar gut bacteriobiota and mycobiota α-diversities compared to those who did not develop VAP. However, gut mycobiota was dissimilar (β-diversity) between these two groups. The presence of Megasphaera massiliensis was associated with the absence of VAP occurrence, whereas the presence of the fungal genus Alternaria sp. was associated with the occurrence of VAP. The composition of the gut microbiota, but not α-diversity, differs between critically ill patients who subsequently develop VAP and those who do not. This study encourages large multicenter cohort studies investigating the role of gut-lung axis and oropharyngeal colonization in the development of VAP in ICU patients. Trial registration number: NCT04131569, date of registration: 18 October 2019. IMPORTANCE The composition of the gut microbiota, but not α-diversity, differs between critically ill patients who subsequently develop ventilator-associated pneumonia (VAP) and those who do not. Investigating gut microbiota composition could help to tailor probiotics to provide protection against VAP.
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.